MedPath

The Effects of Anodal tDCS on Incontinency in Patients with Multiple Sclerosis (MS)

Not Applicable
Conditions
Multiple sclerosis.
Multiple sclerosis
Registration Number
IRCT20201102049234N1
Lead Sponsor
Semnan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
30
Inclusion Criteria

Women with Definitive Diagnosis of MS with Stable Disease over the Previous 4 Months
Definite MS Diagnosis According to the 2010 Revised McDonald Criteria
Age Is Between 18 and 45 Years
Having Symptoms of Urinary Incontinence
Patients Have Received Stable Pharmacological Therapies for the Past 6 Months
Patient's Expanded disability status scale (EDSS) Score Should Be Less than 6.5
Patients Have the Cognitive Capacity to Complete the Assessment and Treatment Protocol
Minimal Ability to Contract the Pelvic Floor Muscles
To Be Willing to Participate in the Study

Exclusion Criteria

History of MS Relapse during Treatment
Being Pregnant or in the First 6 Months Post-Partum
Cesarean Section or Vaginal Delivery within 6 Months Previously to Time of Enrolment
Pelvic Organ Prolapse at Vaginal Examination
Urinary Tract Infection
Having Undergone Surgical Treatment for Urinary Incontinence
Having Undergone Prior Physiotherapy for Urinary Incontinence
The Presence of Any Other Neurological or Kidney Disease
Contraindications of Electrical Stimulation
Declining to Participate in the Study
Inability to Understand and Comply with the Study Procedures

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
evel of urinary incontinence. Timepoint: Before the intervention, 4 and 6 weeks after the start of intervention and one month after the end of intervention. Method of measurement: International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form.;Pelvic floor muscle function. Timepoint: Before the intervention, 4 and 6 weeks after the start of intervention and one month after the end of intervention. Method of measurement: ultrasonographic device.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath